Retatrutide, developed by Soma Pharmaceuticals , is receiving significant attention as a innovative method for obesity regulation. This dual-action compound combines the mechanism of a GLP-1 receptor activator and a GIP receptor stimulant, aiming to simply promote weight loss but also target underlying metabolic conditions . Early human trials have